Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases

This version was published on 1 January 2009

Ann Clin Biochem 2009;46:38-43
doi:10.1258/acb.2008.008088
© 2009 Association for Clinical Biochemistry

 

This Article
Right arrow
Figures Only
Right arrow
Full Text
Right arrow

Full Text (PDF)

Right arrow
All Versions of this Article:

acb.2008.008088v1

46/1/38

most recent

Right arrow
Alert me when this article is cited
Right arrow
Alert me if a correction is posted
Services
Right arrow
Email this article to a friend
Right arrow

Similar articles in this journal

Right arrow
Similar articles in PubMed
Right arrow
Alert me to new issues of the journal
Right arrow
Download to citation manager
Right arrow
Citing Articles
Right arrow

Citing Articles via ISI Web of Science (1)

Google Scholar
Right arrow
Articles by Gu, Y.
Right arrow
Articles by Peng, T.
PubMed
Right arrow
PubMed Citation
Social Bookmarking

What’s this?

Original Articles


Yanli Gu1,
Wenli Chen2,
Yu Zhao1,
Liyun Chen1 and
Tao Peng1


1 Laboratory of Viral Immunology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510663, China;
2 Department of Infectious Diseases, Guangdong Provincial People’s Hospital, Guangzhou 510080, China


Corresponding author: Dr Tao Peng. Email: peng_tao{at}gibh.ac.cn


Background: Golgi protein-73 (GP73) is a newly identified candidate serummarker for liver diseases. The utility of this biomarker remainslimited, largely due to the lack of quantitative information.The aims of this study were to quantify serum GP73 (sGP73) inhealthy individuals and in patients with liver diseases, andto validate sGP73 as a biomarker for early diagnosis of liverdisease.

Methods: Recombinant GP73 was used to generate monoclonal (mAb) and polyclonalantibodies (pAb). Using these antibodies in a quantitative enzyme-linkedimmunosorbent assay, GP73 was measured in serum from 263 patientswith various forms of liver and other diseases.

Results: The median sGP73 in patients with liver disease was significantly higher (P < 0.001) than in healthy individuals and in patientswith other diseases. When sGP73 was used to detect liver disease,it had a sensitivity of 82% and a specificity of 80% at theoptimal cut-off value of 85.5 µg/L. The area under thereceiver-operating characteristic curve was 0.9.

Conclusion: sGP73 concentration in patients with liver disease was three-foldhigher than in healthy individuals. However, sGP73 concentrationsdid not differ significantly between patients from each liverdisease group. Furthermore, sGP73 was not significantly elevatedin patients with diseases other than liver disease comparedwith healthy individuals. These results suggest that sGP73 maybe used as a serum marker for the diagnosis of liver disease.


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What’s this?